FDA panel to discuss Contrave

Orexigen Therapeutics Inc. (NASDAQ:OREX) said FDA tentatively scheduled a meeting of the Metabolic and Endocrine Drug Products Advisory Committee on Dec. 7 to discuss an NDA for Contrave to treat obes...